Rapid Micro Biosystems (NASDAQ:RPID) Stock Moved Up to "Strong-Buy" by Roth Capital

Key Points

• Roth Capital upgraded Rapid Micro Biosystems to “strong buy,” while Weiss Ratings maintained a “sell (D-)” rating. Overall, analysts’ consensus is “Moderate Buy,” with an average price target of $5.00.
• RPID shares opened at $1.08, near their 52-week low of $1.06 and well below the $4.94 high; the company has a market capitalization of approximately $54.2 million.
• Rapid Micro Biosystems reported a quarterly loss of $0.27 per share, missing estimates by $0.03, though revenue of $8.05 million exceeded expectations. The company remains deeply unprofitable, with a negative net margin of 145.56%.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) was upgraded by research analysts at Roth Capital to a "strong-buy" rating in a research report issued on Tuesday, Zacks reports.

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapid Micro Biosystems in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Rapid Micro Biosystems Stock Performance

Shares of RPID stock opened at $1.08 on Tuesday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.51 and a current ratio of 2.55. Rapid Micro Biosystems has a 52 week low of $1.06 and a 52 week high of $4.94. The company's 50 day moving average price is $1.56 and its two-hundred day moving average price is $1.93. The company has a market capitalization of $54.17 million, a P/E ratio of -0.96 and a beta of 1.43.

Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $8.05 million for the quarter, compared to the consensus estimate of $7.88 million. Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. On average, analysts expect that Rapid Micro Biosystems will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Rapid Micro Biosystems

Large investors have recently modified their holdings of the business. Temasek Holdings Private Ltd acquired a new stake in shares of Rapid Micro Biosystems in the first quarter valued at about $50,000. Fifth Lane Capital LP acquired a new position in Rapid Micro Biosystems during the fourth quarter valued at approximately $51,000. Bank of America Corp DE grew its stake in Rapid Micro Biosystems by 139.9% in the first quarter. Bank of America Corp DE now owns 31,014 shares of the company's stock valued at $70,000 after purchasing an additional 18,085 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Rapid Micro Biosystems by 55.9% in the first quarter. Dimensional Fund Advisors LP now owns 87,589 shares of the company's stock valued at $199,000 after purchasing an additional 31,407 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Rapid Micro Biosystems by 9.5% during the 1st quarter. Renaissance Technologies LLC now owns 126,617 shares of the company's stock worth $287,000 after purchasing an additional 10,990 shares during the last quarter. 52.60% of the stock is currently owned by institutional investors and hedge funds.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc develops automated solutions for detecting and monitoring microbial contamination in pharmaceutical, biotechnology, and other regulated manufacturing environments. Its technologies are designed to help companies replace or reduce manual, labor-intensive microbiological testing processes while supporting quality control and regulatory compliance.

The company's primary offering is the Growth Direct platform, an automated microbial detection system that combines instrumentation, consumables, and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.